SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	PIRITEZE ALLERGY TABLETS
Registration number	-
Synonyms	PIRITEZE ALLERGY TABLETS (UK) * PIRITEZE 10 MG TABLETS * MFC 00597 * CETIRIZINE DIHYDROCHLORIDE, FORMULATED PRODUCT
Issue date	13-August-2014
Version number	04
Revision date	13-August-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information None.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3,2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
MICROCRYSTALLINE CELLULOSE	33,0 - 34,0	9004-34-6 232-674-9	-	-	
Classification: **DSD:** -					
CLP: -					
CETIRIZINE DIHYDROCHLORIDE	8,0 - 9,0	83881-52-1 -	-	-	
Classification: **DSD:** Xn;R22					
CLP: Acute Tox. 4;H302					
HYDROXYPROPYL METHYL CELLULOSE	1,0 - 2,0	9004-65-3 -	-	-	
Classification: **DSD:** -					
CLP: -					
MAGNESIUM STEARATE	<1,0	557-04-0 209-150-3	-	-	
Classification: **DSD:** -					
CLP: -					
POLYETHYLENE GLYCOL 400	<1,0	25322-68-3 500-038-2	-	-	
Classification: **DSD:** -					
CLP: -					
Silicon dioxide	<1,0	7631-86-9 231-545-4	-	-	
Classification: **DSD:** -					
CLP: -					
Titanium dioxide	<1,0	13463-67-7 236-675-5	-	-	
Classification: **DSD:** -					
CLP: -					
Other components below reportable levels	50,0 - 55,0				

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.

4.1. Description of first aid measures

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without medical advice.

4.2. Most important symptoms and effects, both acute and delayed The following adverse effects have been noted with therapeutic use of this material: dry mouth; drying of the nasal passages; drowsiness.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing media Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Move containers from fire area if you can do so without risk. Use water spray to cool unopened containers.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Collect spillage. Prevent product from entering drains. Following product recovery, flush area with water.

6.4. Reference to other sections For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value
CETIRIZINE DIHYDROCHLORIDE (CAS 83881-52-1)	OHC	2
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)	OHC	1
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1

GSK Components	Type	Value
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	OHC	1
POLYETHYLENE GLYCOL 400 (CAS 25322-68-3)	OHC	1
Silicon dioxide (CAS 7631-86-9)	OHC	1

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available.

Predicted no effect concentrations (PNECs) Not available.

8.2. Exposure controls

Appropriate engineering controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection Not normally needed. If contact is likely, safety glasses with side shields are recommended. (eg. EN 166)

Skin protection

- Hand protection Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).

- Other Not normally needed. Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust)

Respiratory protection No personal respiratory protective equipment normally required. When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid.

Form Tablet.

Colour White.

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling range Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Solubility (other)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents. Fluorine.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Ingestion	May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational exposure.
Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.
Symptoms	The following adverse effects have been noted with therapeutic use of this material: dry mouth; drying of the nasal passages; drowsiness.

11.1. Information on toxicological effects

Acute toxicity May be harmful if swallowed. Expected to be a low hazard for usual industrial or commercial handling by trained personnel.

Components	Species	Test results
CETIRIZINE DIHYDROCHLORIDE (CAS 83881-52-1)		
Acute		
Oral		
LD50	Rat	365 mg/kg
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg

Components	Species	Test results
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)		
Acute		
Dermal		
LD50	Rabbit	> 2000 mg/kg
Oral		
LD50	Rat	> 2000 mg/kg
POLYETHYLENE GLYCOL 400 (CAS 25322-68-3)		
Acute		
Oral		
LD50	Rat	30,2 g/kg
Titanium dioxide (CAS 13463-67-7)		
Acute		
Inhalation		
LC50	Rat	6820 mcg/m3
Oral		
LD50	Rat	> 24 g/kg
Chronic		
Inhalation		
LOEC	Rat	8,6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years Highest dose 5 mg/m3, 24 months
Subacute		
Inhalation		
LOEL	Rat	0,1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract.
Oral		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.
Subchronic		
Inhalation		
LOEC	Rat	3,2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

TITANIUM DIOXIDE	Acute dermal irritation; OECD 404, Literature data Result: Non-irritant Species: Rabbit Literature data Result: Non-irritant Species: Guinea pig Literature data Result: Non-irritant Species: Human

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE	0

Serious eye damage/eye irritation Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.

Eye

TITANIUM DIOXIDE	OECD 405, Literature data Result: Mild irritant Species: Rabbit

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE	4 Recovery Period: 2 days

Respiratory sensitisation Not available.

Skin sensitisation None known. This product is not expected to cause skin sensitisation.

Maximisation assay (Magnusson and Kligman)

HYDROXYPROPYL METHYL CELLULOSE	Result: negative Species: Guinea pig

Sensitisation

TITANIUM DIOXIDE	5 % Optimisation Test, Literature data - Vehicle: petrolatum Result: negative Species: Guinea pig Test Duration: 48 hour exposure Patch test, Literature data Result: negative Species: Human

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

Mutagenicity

CETIRIZINE DIHYDROCHLORIDE	Ames Result: negative Notes: FDA Approval Package
TITANIUM DIOXIDE	Ames, Literature data Result: negative
CETIRIZINE DIHYDROCHLORIDE	Chromosomal Aberration Assay In Vitro, human lymphocytes Result: negative Notes: FDA Approval Package In vivo Micronucleus Result: negative Species: Mouse Notes: FDA Approval Package In vivo Micronucleus Result: negative Species: Rat
TITANIUM DIOXIDE	Micronucleus Assay in vitro, CHO cells, Literature data Result: negative Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data Result: positive
CETIRIZINE DIHYDROCHLORIDE	Mouse Lymphoma Cell (L5178Y) Mutation Assay Result: negative Notes: FDA Approval Package
TITANIUM DIOXIDE	Syrian Hamster Embryo (SHE) cell transformation assay Result: negative WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell lymphoblastoid, Literature data Result: positive

Carcinogenicity Titanium Dioxide produced carcinogenic effects in a lifetime study in mice High concentrations or doses administered over an extended period of time were required to produce adverse effects.

TITANIUM DIOXIDE	0.5 mg/m3, Literature data Result: negative Species: Rat Test Duration: 24 months 0.72 - 14.8 mg/m3, Literature data Result: negative Species: Mouse 10 - 250 mg/m3, Dietary study - Literature data. Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration. Species: Rat Test Duration: 24 months
CETIRIZINE DIHYDROCHLORIDE	16 mg/kg/day, Species-specific Result: Increase in benign tumours Species: Mouse Organ: Liver Notes: FDA Approval Package 20 mg/kg/day Result: negative Species: Rat Notes: FDA Approval Package

Carcinogenicity

TITANIUM DIOXIDE

25000 - 50000 ppm, Dietary study
Result: negative
Species: Mouse
25000 - 50000 ppm, Dietary study - Literature data.
Result: negative
Species: Rat
7.2 - 14.8 mg/m3, Literature data
Result: Lung tumour
Species: Rat
Test Duration: 24 months

IARC Monographs. Overall Evaluation of Carcinogenicity

SILICON DIOXIDE (CAS 7631-86-9)	3 Not classifiable as to carcinogenicity to humans.
TITANIUM DIOXIDE (CAS 13463-67-7)	2B Possibly carcinogenic to humans.

Reproductive toxicity Contains no ingredient listed as toxic to reproduction

Reproductivity

CETIRIZINE DIHYDROCHLORIDE

135 mg/kg/day Embryo-foetal development
Result: Maternal toxicity; adverse foetal effects
Species: Rabbit
Notes: FDA Approval Package
25 mg/kg/day Embryo-foetal development
Result: Maternal NOAEL, Foetal NOAEL
Species: Rat
Notes: FDA Approval Package
45 mg/kg/day Embryo-foetal development
Result: Maternal NOAEL, Foetal NOAEL
Species: Rabbit
Notes: FDA Approval Package
64 mg/kg/day Female Fertility / Early Embryonic Developmen t Result: negative
Species: Mouse
75 - 225 mg/kg/day Embryo-foetal development
Result: Maternal toxicity; adverse effects on offspring.
Species: Rat
Notes: FDA Approval Package
96 mg/kg/day Embryo-foetal development
Result: Maternal NOAEL, Foetal NOAEL
Species: Mouse
Notes: FDA Approval Package

Specific target organ toxicity - single exposure Not assigned.

Specific target organ toxicity - repeated exposure Not assigned.

Aspiration hazard Not likely, due to the form of the product.

Mixture versus substance information No information available.

Other information Caution - Pharmaceutical agent.

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test results
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)			
Aquatic			
Acute			
Fish	EC50	Fish	> 100 mg/l, 96 hours
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Microtox	EC50	Microtox	12,5 mg/l, 15 minutes

Components		Species	Test results
POLYETHYLENE GLYCOL 400 (CAS 25322-68-3)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	53000 mg/l, 48 hours
Fish	EC50	Fathead minnow (Adult Pimephales promelas)	87000 mg/l, 96 hours
Microtox	EC50	Microtox	100000 mg/l, 15 minutes
Silicon dioxide (CAS 7631-86-9)			
Aquatic			
Acute			
Algae	EC50	Green algae (Selenastrum capricornutum)	440 mg/l, 72 hours
	NOEC	Green algae (Selenastrum capricornutum)	60 mg/l, 72 hours
Crustacea	EC50	Water flea (Daphnia magna)	> 10000 mg/l, 24 hours Static test
Fish	EC50	Common carp (Juvenile Cyprinus carpio)	> 10000 mg/l, 72 hours
		Zebra fish (Adult Brachydanio rerio)	5000 mg/l, 96 hours Static test
Microtox	EC50	Microtox	8700 mg/l, 15 minutes
Titanium dioxide (CAS 13463-67-7)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

POLYETHYLENE GLYCOL 400 40,2 - 70 %, 20 Days BOD20

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

HYDROXYPROPYL METHYL CELLULOSE -5

Bioconcentration factor (BCF)

HYDROXYPROPYL METHYL CELLULOSE 3,2 Estimated

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5,86 Estimated

Mobility in general Not available.

Volatility

Henry's law

HYDROXYPROPYL METHYL CELLULOSE 0 atm m3/mol Estimated

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
EU waste code	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Disposal methods/information	Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Observe all local and national regulations when disposing of this product. Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Special precautions	Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.
National regulations	Follow national regulation for work with chemical agents.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R22 Harmful if swallowed. H302 Harmful if swallowed.
Revision information	Product and Company Identification: Product and Company Identification Composition / Information on Ingredients: Undisclosed Ingredient Statement Physical & Chemical Properties: Regulatory Information: United States GHS: Classification
Training information	Follow training instructions when handling this material.
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.